Founded with a mission to redefine the standard of care for iron deficiency, Keylika is an early-stage biopharma startup focused on developing metal-based drugs using a proprietary platform synthesis technology. The company aims to address unmet medical needs through innovative drug delivery systems. Keylika's flagship product is a small molecule iron drug, a new molecular entity, delivered via a wearable skin patch to treat Iron Deficiency Anemia (IDA). This product promises significantly higher safety, efficacy, and tolerability compared to existing treatments.
Keylika has garnered attention from notable investors and industry experts who recognize its potential to revolutionize the treatment of IDA. The company's innovative approach and promising clinical outcomes have positioned it as a key player in the biopharma landscape. By focusing on both cutting-edge drug development and proven delivery technologies, Keylika aims to make a substantial impact on patient care and set new standards in the treatment of iron deficiency.
